Business Segments · Subtotal
Oncology & Multispecialty — Subtotal
McKesson Oncology & Multispecialty — Subtotal remained flat by 0.0% to $287.25M in Q4 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.5%, from $304M to $287.25M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ3 2024
Last reportedQ4 2026May 8, 2026
How to read this metric
An increase indicates growth in the segment's operational scale or profitability, while a decrease signals a contraction or margin pressure.
Detailed definition
Represents the aggregate financial performance or operational sub-total for the Oncology and Multispecialty segment befo...
Peer comparison
Comparable to 'Segment Operating Profit' or 'Segment Revenue' sub-totals reported by peer healthcare distribution companies.
Metric ID:
mck_segment_oncology_multispecialty_subtotalHistorical Data
8 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $200M | $202M | $332M | $304M | $287.25M | $287.25M | $287.25M | $287.25M |
| QoQ Change | — | +1.0% | +64.4% | -8.4% | -5.5% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | +66.0% | +50.5% | — | — | -13.5% | -5.5% |
Range$200M – $332M
CAGR+23.0%
Avg YoY Growth+24.4%
Median YoY Growth+22.5%
Current Streak3 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — subtotal?
- McKesson (MCK) reported oncology & multispecialty — subtotal of $287.25M in Q4 2026.
- How has McKesson's oncology & multispecialty — subtotal changed year-over-year?
- McKesson's oncology & multispecialty — subtotal decreased by 5.5% year-over-year, from $304M to $287.25M.
- What does oncology & multispecialty — subtotal mean?
- The combined financial sub-total for the Oncology and Multispecialty business segment.